https://www.selleckchem.com/pr....oducts/z-vad(oh)-fmk
The effectiveness of Ustekinumab (UST) on Crohn's disease(CD)-associated spondyloarthropathy (SpA) is currently unknown. All consecutive CD patients with active SpA at the initiation of the treatment with UST were extracted from the cohort of the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). The primary outcome was the articular response at 8 and 24weeks, defined as the disappearance of objective signs of arthritis (swelling and/or articular stiffness) and resolution of pain. Thirty CD patients with active SpA at the
Like
Comment
Share
